Telix Pharmaceuticals Submits Brain Cancer Imaging Agent TLX101-Px for Regulatory Approval
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.